CDH2 and neoplasm: Phenotypic shifts, such as epithelial-to-mesenchymal transition (EMT), can be monitored during tumor progression through the use of lineage tracing models, such as those that follow N-cadherin expression [23] or follow unique barcodes genetically encoded into individual tumor cells [24–26].